Basmina Parmakhtiar, Ph.D.
Affiliations: | 2012 | Biomedical Sciences - Ph.D. | University of California, Irvine, Irvine, CA |
Area:
Biochemistry, Pharmacology, Pharmacy, OncologyGoogle:
"Basmina Parmakhtiar"Parents
Sign in to add mentor| John P. Fruehauf | grad student | 2012 | UC Irvine | |
| (Targeting Hypoxia-Inducible Factor to Reverse Drug Resistance in Cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Parmakhtiar B, Burger RA, Kim JH, et al. (2019) HIF inactivation of p53 in Ovarian Cancer Can be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity. Molecular Cancer Research : McR |
| Fruehauf JP, El-Masry M, Osann K, et al. (2018) Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology |
| Chung CT, Piro LD, Lieber D, et al. (2015) Selecting optimal patient candidates to assess the clinical utility of patient-derived xenograft (PDX) models in advanced solid tumors. Journal of Clinical Oncology. 33: e22186-e22186 |
| Ein-Gal SY, Tsang W, Alger B, et al. (2013) Updated interim analysis of UCI 09-53: A phase II, single arm study of pazopanib and paclitaxel as first-line treatment for subjects with unresectable advanced melanoma. Journal of Clinical Oncology. 31: 9082-9082 |
| Fruehauf JP, Alger B, Parmakhtiar B, et al. (2012) A phase II single arm study of pazopanib and paclitaxel as first-line treatment for unresectable stage III and stage IV melanoma: Interim analysis. Journal of Clinical Oncology. 30: 8524-8524 |
| Tang Y, Parmakhtiar B, Simoneau AR, et al. (2011) Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia (New York, N.Y.). 13: 108-19 |
| Parmakhtiar B, Trapp V, Mossavat M, et al. (2011) Abstract 2533: Synergistic interactions between topotecan and resveratrol in melanoma Cancer Research. 71: 2533-2533 |
| Parmakhtiar B, Trapp V, Burger RA, et al. (2011) Abstract C208: Chemosensitization of ovarian cancer after topotecan modulation of HIF and p53. Molecular Cancer Therapeutics. 10 |
| Trapp V, Parmakhtiar B, Papazian V, et al. (2010) Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis. 13: 305-15 |
| Han ES, Burger RA, Darcy KM, et al. (2010) Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecologic Oncology. 119: 484-90 |